Volume 27, Number 1—January 2021
Synopsis
Aspergillosis Complicating Severe Coronavirus Disease
Table
Patient no. | Age, y/sex | Underlying condition | Previous IS | Days from ICU to CAPA | Days from symptoms to CAPA | CT result† | BDG assay | GM assay | GM BAL | Respiratory culture | Outcome |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 71/F | COPD, ESRD | Neg | 8 | 9 | GGO, nodulesA | Pos | Neg | ND | A. fumigatus‡ | Survived |
2 | 56/F | COPD, DM, HTN, CHF, obesity | Neg | 2 | 2 | GGO, nodulesB | ND | Pos | ND | ND | Survived |
3 | 70/F | HTN | Neg | 10 | 10 | ND | Pos | Pos | ND | ND | Died |
4 | 68/F | HTN, dementia | Neg | 2 | 4 | ND | ND | Neg | ND | A. fumigatus‡ | Survived |
5 | 69/M | HTN | Neg | 12 | 13 | GGO, consolidationsC | ND | Neg | ND | A. niger‡ | Died |
6 | 55/M | Quadriplegia, HTN, CAD | Neg | −1 | 1 | GGO, consolidationsD | Neg | Neg | ND | A. fumigatus‡ | Survived |
7 | 85/F | DM, HTN, ESRD | Neg | 9 | 11 | Consolidations, nodules, cavitiesE | Pos | Pos | ND | A. fumigatus‡ | Survived |
8 | 50/F | ESRD, asthma | Tocilizumab | 23 | ND | ND | Pos | Neg | ND | A. fumigatus‡ | Survived |
9 | 45/F | MS, SLE, asthma | Ocrelizumab | 12 | 23 | GGO, consolidations, airway wall thickeningF | Int | Neg | ND | A. fumigatus§ | Survived |
10 | 57/F | DM | Neg | 4 | 13 | ND | Neg | Neg | ND | A. fumigatus‡ | Survived |
11 | 57/M | Lymphoma | Rituximab | 22 | 5 | ND | Int | Neg | ND | A. fumigatus‡ | Survived |
12 | 61/M | HTN | Neg | 16 | 11 | ND | Neg | Pos | ND | Neg | Died |
13 | 75/F | HTN, COPD, DM, obesity | Neg | 12 | 14 | ND | ND | ND | ND | A. fumigatus‡ | Survived |
14 | 56/F | Asthma | Tocilizumab | 2 | 8 | ND | ND | Neg | ND | A. fumigatus‡ | Survived |
15 | 70/M | HTN | Neg | 3 | 9 | ConsolidationsG | ND | ND | ND | A. fumigatus‡, A. niger‡ | Survived |
16 | 76/M | COPD | Steroids | 11 | 14 | ND | ND | Neg | ND | A. fumigatus†, A. niger† | Survived |
17 | 73/M | HTN, DM | Steroids | 7 | 13 | GGO, consolidationsH | ND | Neg | ND | Aspergillus spp‡ | Survived |
18 | 78/M | HTN, prosthetic mitral valve | Steroids, siltuximab | 14 | 16 | ND | ND | ND | ND | Aspergillus spp.‡ | Survived |
19 | 56/F | None | Tocilizumab, anakinra | 9 | 19 | ND | ND | ND | ND | A. terreus§ | Survived |
20 | 81/M | DM, HTN, cirrhosis | Steroid | 24 | 39 | Consolidations, cavityI | ND | Neg | Pos | A. niger§ | Survived |
Total | 55% F, mean age 65.5 y (range 45–81 y) | HTN 60%; COPD/asthma 35%; DM 30%, ESRD 15% | Steroids (4/20, 20%); other (6/20, 30%) | Median 9.5 (range −1 to 24) | Median 11 (range 1–42) | pos 4/9 (44%); neg 3/9 (33%); int 2/9 (22%) | pos 4/16 (25%); neg 12/16 (75%) | 0/1 | Culture pos 3 BAL, 14 airways | Died 3/20 (15%) |
*Patients 1–12 were from the United States, and patients 13–20 were from Spain. BAL, bronchioalveolar lavage; BGD, β-